增加的氧气刺激促进化学抵抗和表型转移通过PLCB1在质瘤
Kang Ma1, Shi Wang1, Yingjie Ma2
1Glioma Medical Research Center and Department of Neurosurgery, The First Affiliated Hospital, Third Military Medical University (Army Medical University), Chongqing 400038, China.
概括
增加的氧气会通过上调 miR-1290,下调 PLCB1 和激活 Wnt 信号来加剧质瘤的化学抵抗. 这表明,在质瘤患者的高压氧气治疗中应谨慎.
科学领域:
- 神经瘤学神经瘤学
- 癌症生物学 癌症生物学
- 分子机制的分子机制
背景情况:
- 质瘤是常见的中枢神经系统 (CNS) 瘤,由于化学抵抗,其存活率很低,通常与缺氧有关.
- 人们对氧气水平的变化如何影响质瘤化疗敏感性和对氧气刺激的反应的理解有限.
研究的目的:
- 为了研究增加氧气刺激对质瘤生长和化学抵抗的影响.
- 阐明基质瘤中氧气诱导的化学抵抗背后的分子机制.
- 评估Wnt抑制和PLCB1作为生物标志物的治疗潜力.
主要方法:
- 研究了增加氧气对质瘤细胞和质瘤携带的小鼠模型的影响.
- 利用分子生物学技术识别关键信号通路,包括miR-1290,PLCB1和β-catenin.
- 在体内评估WNT974 (Wnt抑制剂) 的疗效,并分析PLCB1表达的预后价值.
主要成果:
- 增加氧气刺激促进了质瘤的生长和化学抵抗.
- 在机械上,氧气上调 miR-1290,从而降低了 PLCB1 的调节,导致β-catenin 积累,并增强了 Wnt 信号传输.
- 药理上的Wnt抑制部分降低了瘤生长,并改善了小鼠的存活率;PLCB1显示出作为预后生物标志物的潜力.
结论:
- 增加的氧气通过miR-1290/PLCB1/β-catenin/Wnt通路促进质瘤的进展和化学抵抗.
- 抑制Wnt通路提供了一个潜在的治疗策略.
- PLCB1可以作为一种有价值的生物标志物,用于质瘤分级和预后.
- 这些发现突显了质瘤患者的高压氧气治疗 (HBOT) 的潜在风险,特别是作为独立治疗或与化学疗法结合而不是放射治疗.
相关概念视频
02:53Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K